Paratek Pharmaceuticals Statistics
Share Statistics
Paratek Pharmaceuticals has 57.32M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 57.32M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 110,528 |
| FTD / Avg. Volume | 18.43% |
Short Selling Information
The latest short interest is 2.75M, so 4.81% of the outstanding
shares have been sold short.
| Short Interest | 2.75M |
| Short % of Shares Out | 4.81% |
| Short % of Float | 5.83% |
| Short Ratio (days to cover) | 6.27 |
Valuation Ratios
The PE ratio is -1.6 and the forward
PE ratio is null.
Paratek Pharmaceuticals's PEG ratio is
0.39.
| PE Ratio | -1.6 |
| Forward PE | n/a |
| PS Ratio | 0.67 |
| Forward PS | n/a |
| PB Ratio | -0.59 |
| P/FCF Ratio | -1.54 |
| PEG Ratio | 0.39 |
Financial Ratio HistoryEnterprise Valuation
Paratek Pharmaceuticals has an Enterprise Value (EV) of 325.87M.
| EV / Sales | 2.16 |
| EV / EBITDA | -7.26 |
| EV / EBIT | -4.93 |
| EV / FCF | -4.92 |
Financial Position
The company has a current ratio of 3.66,
with a Debt / Equity ratio of -1.51.
| Current Ratio | 3.66 |
| Quick Ratio | 3.22 |
| Debt / Equity | -1.51 |
| Debt / EBITDA | -5.76 |
| Debt / FCF | -3.9 |
| Interest Coverage | -2.55 |
Financial Efficiency
Return on Equity is 37.16% and Return on Invested Capital is -52.94%.
| Return on Equity | 37.16% |
| Return on Assets | -36.84% |
| Return on Invested Capital | -52.94% |
| Revenue Per Employee | $562,641.79 |
| Profits Per Employee | $-237,186.57 |
| Employee Count | 268 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.39 |
Taxes
| Income Tax | 57K |
| Effective Tax Rate | -0.09% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.7, so Paratek Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.7 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.2 |
| 200-Day Moving Average | 2.07 |
| Relative Strength Index (RSI) | 59.19 |
| Average Volume (20 Days) | 599,679 |
Income Statement
In the last 12 months, Paratek Pharmaceuticals had revenue of 150.79M
and earned -63.57M
in profits. Earnings per share was -1.17.
| Revenue | 150.79M |
| Gross Profit | 127.73M |
| Operating Income | -46.21M |
| Net Income | -63.57M |
| EBITDA | -44.9M |
| EBIT | -45.39M |
| Earnings Per Share (EPS) | -1.17 |
Full Income StatementBalance Sheet
The company has 34.25M in cash and 258.41M in
debt, giving a net cash position of -224.17M.
| Cash & Cash Equivalents | 34.25M |
| Total Debt | 258.41M |
| Net Cash | -224.17M |
| Retained Earnings | -930.45M |
| Total Assets | 145.79M |
| Working Capital | -97.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -66.14M
and capital expenditures -36K, giving a free cash flow of -66.18M.
| Operating Cash Flow | -66.14M |
| Capital Expenditures | -36K |
| Free Cash Flow | -66.18M |
| FCF Per Share | -1.22 |
Full Cash Flow StatementMargins
Gross margin is 84.71%, with operating and profit margins of -30.65% and -42.16%.
| Gross Margin | 84.71% |
| Operating Margin | -30.65% |
| Pretax Margin | -42.12% |
| Profit Margin | -42.16% |
| EBITDA Margin | -29.78% |
| EBIT Margin | -30.65% |
| FCF Margin | -43.89% |
